Application of a Glycoproteomics-Based Biomarker Development Method: Alteration in Glycan Structure on Colony Stimulating Factor 1 Receptor as a Possible Glycobiomarker Candidate for Evaluation of Liver Cirrhosis

• DOI: 10.1021/pr400986t
• Publication Date: 2014-01-15T13:16:22Z
• Authors: Makoto Ocho; Akira Togayachi; Etsuko Iio; Hiroyuki Kaji; Atsushi Kuno; Maki Sogabe; Masaaki Korenaga; Masanori Gotoh; Yasuhito Tanaka; Yuzuru Ikehara; Masashi Mizokami; Hisashi Narimatsu
• Keywords: Adult; Aged, 80 and over; Liver Cirrhosis; Male; Proteomics; 0301 basic medicine; Protein Array Analysis; Enzyme-Linked Immunosorbent Assay; Receptor, Macrophage Colony-Stimulating Factor; Hepatitis C, Chronic; Middle Aged; 3. Good health; 03 medical and health sciences; Hepatitis B, Chronic; Polysaccharides; Carbohydrate Conformation; Feasibility Studies; Humans; Female; Plant Lectins; Biomarkers; Aged; Glycoproteins

The importance of diagnosis and therapies for liver cirrhosis (LC) is indisputable. Thus, a reliable method for monitoring the progression of liver fibrosis and resultant LC is urgently needed. Previously, using a lectin-assisted glycoproteomic method, we identified 26 serum glycoproteins as promising glycobiomarker candidates for monitoring the progression of liver diseases. In this study, we identified colony stimulating factor 1 receptor (CSF1R) as a promising LC marker candidate and then established Wisteria floribunda agglutinin (WFA)-reactive CSF1R (WFA(+)-CSF1R) as a novel possible glycobiomarker candidate by utilizing a glycoproteomics-based strategy. The serum level of WFA(+)-CSF1R in patients with hepatitis C virus (HCV)-infected liver disease was measured by an antibody-lectin sandwich ELISA. In a proof-of-concept experiment of the strategy preceding to future clinical studies, LC patients showed a high serum WFA(+)-CSF1R level in selected samples (P = 1.3 × 10(-17)). This result suggests WFA(+)-CSF1R is a possible biomarker candidate for evaluation of LC. Our results verified feasibility of this strategy for glycobiomarker development.